SG3 Management’s AbbVie ABBV Stock Holding History

SG3 Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,000	Closed	-$2.32M	–	904
2021 Q4	$2.17M	Buy	16,000 +12,500	+357%	+$1.48M	0.04%	327
2021 Q3	$378K	Sell	3,500 -8,500	-71%	-$971K	0.01%	653
2021 Q2	$1.35M	Buy	+12,000	New	+$1.35M	0.05%	393
2020 Q3	–	Sell	-20,000	Closed	-$1.88M	–	864
2020 Q2	$1.96M	Buy	+20,000	New	+$1.76M	0.14%	194

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SG3 Management's ABBV Position: Q1 2022 in Review

SG3 Management sold out of AbbVie (ABBV) in Q1 2022, closing a stake of 16,000 shares — an estimated $2.32M sold.

SG3 Management first reported a position in ABBV in Q2 2020 and held it in 4 quarters. The position peaked at $2.17M in Q4 2021. 3,052 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

SG3 Management reported no remaining AbbVie position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 16,000 AbbVie shares in Q1 2022, an estimated $2.32M.
SG3 Management first reported a position in AbbVie in Q2 2020 and held it in 4 quarters.
SG3 Management's AbbVie position peaked at $2.17M in Q4 2021.
3,052 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.